Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Retained Earnings (2016 - 2026)

Sunshine Biopharma filings provide 14 years of Retained Earnings readings, the most recent being -$75.0 million for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 8.65% to -$75.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$75.0 million, a 8.65% decrease, with the full-year FY2025 number at -$75.0 million, down 8.65% from a year prior.
  • Retained Earnings hit -$75.0 million in Q4 2025 for Sunshine Biopharma, down from -$320841.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $696105.0 in Q4 2023 to a low of -$75.0 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$27.8 million (2021), compared with a mean of -$26.9 million.
  • Biggest five-year swings in Retained Earnings: crashed 688217.34% in 2021 and later soared 330.1% in 2023.
  • Sunshine Biopharma's Retained Earnings stood at -$32.7 million in 2021, then surged by 100.5% to $161847.0 in 2022, then surged by 330.1% to $696105.0 in 2023, then plummeted by 10018.01% to -$69.0 million in 2024, then dropped by 8.65% to -$75.0 million in 2025.
  • The last three reported values for Retained Earnings were -$75.0 million (Q4 2025), -$320841.0 (Q3 2025), and -$72.0 million (Q2 2025) per Business Quant data.